Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/47773
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMenekse S.-
dc.contributor.authorDeniz S.-
dc.date.accessioned2023-01-09T21:30:00Z-
dc.date.available2023-01-09T21:30:00Z-
dc.date.issued2022-
dc.identifier.issn2036-6590-
dc.identifier.urihttps://doi.org/10.3855/jidc.15637-
dc.identifier.urihttps://hdl.handle.net/11499/47773-
dc.description.abstractIntroduction: We sought to evaluate secondary infections (SIs) in patients admitted to the intensive care unit (ICU) for COVID-19 with respect to incidence, causative pathogens, and clinical outcomes. Methodology: In this two-centre retrospective study, we analysed 146 patients (96 males, 50 females; median age, 64 years) admitted to the ICU with COVID-19 between March 26 and December 31, 2020. Inclusion criteria were an ICU admission for at least 48 hours and age beyond 18 years. Patients with and without SIs were compared and the impacts of SIs and carbapenem resistance on mortality were analysed. Results: During ICU admission, 84 episodes of SIs developed in 58 patients (39.7%). A total of 104 isolates were recovered, with Gram-negative bacteria most frequent accounting for 74%. At least one carbapenem-resistant pathogen (n = 61) was recovered in 41 patients (70.1%). In multivariate analysis, the use of ECMO and an elevated procalcitonin level were significantly associated with the development of SIs. The mortality rate and the incidence of carbapenem resistance did not differ significantly in COVID-19 patients with and without SIs (p = 0.059 and p = 0.083, respectively). Conclusions: The incidences of SIs and carbapenem resistance among COVID-19 patients were alarming, emphasizing stricter infection control measures in the ICU setting. © 2022 Journal of Infection in Developing Countries. All rights reserved.en_US
dc.language.isoenen_US
dc.publisherJournal of Infection in Developing Countriesen_US
dc.relation.ispartofJournal of Infection in Developing Countriesen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCarbapenem resistanceen_US
dc.subjectCOVID-19en_US
dc.subjectIntensive care unit infections.en_US
dc.subjectSecondary infectionsen_US
dc.subjectcarbapenemen_US
dc.subjectconvalescent plasmaen_US
dc.subjectprocalcitoninen_US
dc.subjectsteroiden_US
dc.subjecttocilizumaben_US
dc.subjectcarbapenem derivativeen_US
dc.subjectAcinetobacter baumanniien_US
dc.subjectadulten_US
dc.subjectadult respiratory distress syndromeen_US
dc.subjectageden_US
dc.subjectantibiotic sensitivityen_US
dc.subjectAPACHEen_US
dc.subjectArticleen_US
dc.subjectbacteriumen_US
dc.subjectCandidaen_US
dc.subjectcarbapenem resistanceen_US
dc.subjectcoagulase negative Staphylococcusen_US
dc.subjectcoronavirus disease 2019en_US
dc.subjectdays from diagnosis to discharge or mortalityen_US
dc.subjectduration of central catheteren_US
dc.subjectduration of extracorporeal oxygenationen_US
dc.subjectduration of invasive ventilationen_US
dc.subjectEnterobacter aerogenesen_US
dc.subjectEnterococcusen_US
dc.subjectEscherichia colien_US
dc.subjectextracorporeal oxygenationen_US
dc.subjectfemaleen_US
dc.subjectHorowitz indexen_US
dc.subjecthumanen_US
dc.subjectintensive care uniten_US
dc.subjectKlebsiella pneumoniaeen_US
dc.subjectlength of stayen_US
dc.subjectmaleen_US
dc.subjectmethicillin resistant Staphylococcus aureusen_US
dc.subjectmethicillin susceptible Staphylococcus aureusen_US
dc.subjectmicrobiological examinationen_US
dc.subjectmortality rateen_US
dc.subjectobservational studyen_US
dc.subjectphysical parametersen_US
dc.subjectProvidencia rettgerien_US
dc.subjectPseudomonas aeruginosaen_US
dc.subjectretrospective studyen_US
dc.subjectsecondary infectionen_US
dc.subjectseptic shocken_US
dc.subjectSequential Organ Failure Assessment Scoreen_US
dc.subjectSerratia marcescensen_US
dc.subjectSphingomona paucimobilisen_US
dc.subjectStenotrophomonas maltophiliaen_US
dc.subjectadolescenten_US
dc.subjectcoinfectionen_US
dc.subjectepidemiologyen_US
dc.subjectmiddle ageden_US
dc.subjectAdolescenten_US
dc.subjectCarbapenemsen_US
dc.subjectCoinfectionen_US
dc.subjectCOVID-19en_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectIntensive Care Unitsen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectRetrospective Studiesen_US
dc.titleSecondary infections in COVID-19 patients: A two-centre retrospective observational studyen_US
dc.typeArticleen_US
dc.identifier.volume16en_US
dc.identifier.issue8en_US
dc.identifier.startpage1294en_US
dc.identifier.endpage1301en_US
dc.identifier.doi10.3855/jidc.15637-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid57200030180-
dc.authorscopusid56556385600-
dc.identifier.pmid36099372en_US
dc.identifier.scopus2-s2.0-85137809567en_US
dc.identifier.wosWOS:000890137900008en_US
dc.identifier.scopusqualityQ3-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextopen-
item.fulltextWith Fulltext-
item.languageiso639-1en-
item.openairetypeArticle-
item.cerifentitytypePublications-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Files in This Item:
File SizeFormat 
Secondary infections in COVID-19.pdf563.38 kBAdobe PDFView/Open
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

3
checked on Oct 13, 2024

WEB OF SCIENCETM
Citations

2
checked on Oct 31, 2024

Page view(s)

44
checked on Aug 24, 2024

Download(s)

12
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.